{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T08:59:07Z","timestamp":1758704347837,"version":"3.41.2"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00719","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T05:27:25Z","timestamp":1588051645000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA\/MVA-CMDR Immunization and a Late MVA-CMDR Boost"],"prefix":"10.3389","volume":"11","author":[{"given":"Agricola","family":"Joachim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed I. M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Pollakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena S.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Munseri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Said","family":"Aboud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eligius F.","family":"Lyamuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Bakari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merlin L.","family":"Robb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"Wahren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Sandstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotta","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnel","family":"Biberfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Geldmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Held","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8932","DOI":"10.1128\/JVI.01190-15","article-title":"Cell- and protein-directed glycosylation of native cleaved HIV-1 envelope","volume":"89","author":"Pritchard","year":"2015","journal-title":"J Virol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"14954","DOI":"10.1038\/ncomms14954","article-title":"Global site-specific N-glycosylation analysis of HIV envelope glycoprotein","volume":"8","author":"Cao","year":"2017","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/QAD.0000000000000106","article-title":"Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection","volume":"28","author":"Hraber","year":"2014","journal-title":"AIDS"},{"key":"B4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.tim.2014.12.007","article-title":"Virological features associated with the development of broadly neutralizing antibodies to HIV-1","volume":"23","author":"Moore","year":"2015","journal-title":"Trends Microbiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"358ra125","DOI":"10.1126\/scitranslmed.aag1048","article-title":"Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection","volume":"8","author":"Muenchhoff","year":"2016","journal-title":"Sci Transl Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.1128\/JVI.00110-09","article-title":"Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm","volume":"83","author":"Simek","year":"2009","journal-title":"J Virol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3389\/fimmu.2017.01057","article-title":"Env-specific antibodies in chronic infection versus in vaccination","volume":"8","author":"Soldemo","year":"2017","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e75665","DOI":"10.1371\/journal.pone.0075665","article-title":"Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial","volume":"8","author":"Gottardo","year":"2013","journal-title":"PLoS ONE"},{"key":"B11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3389\/fimmu.2019.00717","article-title":"Envelope-specific recognition patterns of HIV vaccine-induced IgG antibodies are linked to immunogen structure and sequence","volume":"10","author":"Nadai","year":"2019","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature11519","article-title":"Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2","volume":"490","author":"Rolland","year":"2012","journal-title":"Nature."},{"key":"B13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ebiom.2014.10.022","article-title":"Vaccine-induced human antibodies specific for the third variable region of HIV-1 gp120 impose immune pressure on infecting viruses","volume":"1","author":"Zolla-Pazner","year":"2014","journal-title":"EBioMedicine."},{"key":"B14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nature10766","article-title":"Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys","volume":"482","author":"Barouch","year":"2012","journal-title":"Nature."},{"key":"B15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1473-3099(12)70088-9","article-title":"Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B\/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144","volume":"12","author":"Robb","year":"2012","journal-title":"Lancet Infect Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1089\/aid.2016.0204","article-title":"Comparison of antibody responses induced by RV144, VAX003, and VAX004 vaccination regimens","volume":"33","author":"Karnasuta","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B17","doi-asserted-by":"publisher","first-page":"228ra39","DOI":"10.1126\/scitranslmed.3007730","article-title":"Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination","volume":"6","author":"Yates","year":"2014","journal-title":"Sci Transl Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.immuni.2012.11.011","article-title":"Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nri2801","article-title":"Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design","volume":"10","author":"Zolla-Pazner","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"9808","DOI":"10.1128\/JVI.71.12.9808-9812.1997","article-title":"Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein","volume":"71","author":"Cao","year":"1997","journal-title":"J Virol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"8055","DOI":"10.1073\/pnas.86.20.8055","article-title":"Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers","volume":"86","author":"Rossi","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"B22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/ni1566","article-title":"HIV-1 envelope protein binds to and signals through integrin \u03b14\u03b27, the gut mucosal homing receptor for peripheral T cells","volume":"9","author":"Arthos","year":"2008","journal-title":"Nat Immunol."},{"key":"B23","first-page":"128","article-title":"Prevalence of a V2 epitope in clade B primary isolates and its recognition by sera from HIV-1-infected individuals","volume":"11","author":"Israel","year":"1997","journal-title":"AIDS."},{"key":"B24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3233\/HAB-2005-143-403","article-title":"Improving on nature: focusing the immune response on the V3 loop","volume":"14","author":"Zolla-Pazner","year":"2005","journal-title":"Hum Antibodies."},{"key":"B25","doi-asserted-by":"publisher","first-page":"8417","DOI":"10.1016\/j.vaccine.2011.08.001","article-title":"Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania","volume":"29","author":"Bakari","year":"2011","journal-title":"Vaccine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0118486","DOI":"10.1371\/journal.pone.0118486","article-title":"Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults","volume":"10","author":"Joachim","year":"2015","journal-title":"PLoS ONE"},{"key":"B27","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1089\/aid.2016.0251","article-title":"Three-year durability of immune responses induced by HIV-DNA and HIV-modified Vaccinia Virus ankara and effect of a late HIV-modified Vaccinia Virus ankara boost in Tanzanian volunteers","volume":"33","author":"Joachim","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e00339","DOI":"10.1016\/j.heliyon.2017.e00339","article-title":"HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV","volume":"3","author":"Hinkula","year":"2017","journal-title":"Heliyon"},{"key":"B29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1006\/viro.2002.1547","article-title":"Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes","volume":"302","author":"Ljungberg","year":"2002","journal-title":"Virology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.ymthe.2005.06.473","article-title":"Multigene\/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery","volume":"12","author":"Br\u00e5ve","year":"2005","journal-title":"Mol Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1038\/sj.mt.6300235","article-title":"A new multi-clade DNA prime\/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice","volume":"15","author":"Br\u00e5ve","year":"2007","journal-title":"Mol Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1086\/592507","article-title":"Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara","volume":"198","author":"Sandstr\u00f6m","year":"2008","journal-title":"J Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1101\/gr.849004","article-title":"WebLogo: a sequence logo generator","volume":"14","author":"Crooks","year":"2004","journal-title":"Genome Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0119629","DOI":"10.1371\/journal.pone.0119629","article-title":"Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial","volume":"10","author":"Munseri","year":"2015","journal-title":"PLoS ONE."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0155702","DOI":"10.1371\/journal.pone.0155702","article-title":"Boosting with subtype C CN54rgp140 protein adjuvanted with glucopyranosyl lipid adjuvant after priming with HIV-DNA and HIV-MVA is safe and enhances immune responses: a phase I trial","volume":"11","author":"Joachim","year":"2016","journal-title":"PLoS ONE."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1089\/aid.2012.0103","article-title":"The Thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120","volume":"28","author":"Karasavvas","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e53629","DOI":"10.1371\/journal.pone.0053629","article-title":"Analysis of V2 antibody responses induced in vaccinees in the ALVAC\/AIDSVAX HIV-1 vaccine efficacy trial","volume":"8","author":"Zolla-Pazner","year":"2013","journal-title":"PLoS ONE"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/infdis\/jix099","article-title":"Randomized, double-blind evaluation of late boost strategies for HIV-uninfected vaccine recipients in the RV144 HIV vaccine efficacy trial","volume":"215","author":"Rerks-Ngarm","year":"2017","journal-title":"J Infect Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1016\/S2352-3018(18)30071-7","article-title":"Subtype C ALVAC-HIV and bivalent subtype C gp120\/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1\/2 trial","volume":"5","author":"Bekker","year":"2018","journal-title":"Lancet HIV"},{"key":"B40","doi-asserted-by":"publisher","first-page":"228ra38","DOI":"10.1126\/scitranslmed.3007736","article-title":"Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines","volume":"6","author":"Chung","year":"2014","journal-title":"Sci Transl Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jim.2014.11.006","article-title":"Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development","volume":"416","author":"Stephenson","year":"2015","journal-title":"J Immunol Methods"},{"key":"B42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3389\/fimmu.2017.00149","article-title":"A comparative phase i study of combination, homologous subtype-C DNA, MVA, and Env gp140 protein\/adjuvant HIV vaccines in two immunization regimes","volume":"8","author":"Joseph","year":"2017","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3389\/fimmu.2017.00595","article-title":"A phase 1 human immunodeficiency virus vaccine trial for cross-profiling the kinetics of serum and mucosal antibody responses to CN54gp140 modulated by two homologous prime-boost vaccine regimens","volume":"8","author":"Kratochvil","year":"2017","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1600-0854.2006.00528.x","article-title":"Macrophage activation downregulates the degradative capacity of the phagosome","volume":"8","author":"Yates","year":"2007","journal-title":"Traffic"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e131437","DOI":"10.1172\/jci.insight.131437","article-title":"HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions","volume":"5","author":"Easterhoff","year":"2020","journal-title":"JCI Insight"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00719\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T05:28:57Z","timestamp":1588051737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00719\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2020.00719"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00719","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2020,4,28]]},"article-number":"719"}}